MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+
Main Authors: | F. Barata, H. Queiroga, E. Teixeira, M.T. Almodovar, B. Parente, M. Soares |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-09-01
|
Series: | Revista Portuguesa de Pneumologia (English Edition) |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2173511516300148 |
Similar Items
-
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
by: F. Barata, et al.
Published: (2021-03-01) -
The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
by: Baohui HAN, et al.
Published: (2009-12-01) -
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01) -
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01) -
Treatment of Advanced NSCLC with Unknown EGFR Gene Status
__ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01)